Clinical Trial Update: LENS - Long-term Eltrombopag Observational Study

View source ↗

Summary

The LENS long-term observational study evaluating eltrombopag in idiopathic thrombocytopenic purpura has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Promacta (eltrombopag)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Purpura, Thrombocytopaenic, Idiopathic | Status: COMPLETED